Tag

Autoimmune Disease

All articles tagged with #autoimmune disease

entertainment2 days ago•7 min saved

Joe Manganiello's Memoir 'Bloodlines' Reveals Autoimmune Illness and Dispute with Ex-Wife Sofia Vergara

Actor Joe Manganiello has detailed a seven-year battle with an undiagnosed autoimmune illness in his upcoming memoir, 'Bloodlines,' which he claims contributed to the breakdown of his marriage to Sofia Vergara. The book, releasing on October 13, alleges that Vergara mocked him and refused physical affection during his recovery, contradicting her previous public statements that their divorce stemmed from disagreements over having children. Manganiello, who is now symptom-free and engaged to Caitlin O'Connor, credits a shaman and surgery for his recovery.

via Just Jared|

#autoimmune-disease #bloodlines #caitlin-oconnor

entertainment2 days ago•20 min saved

Manganiello Accuses Vergara of Mocking His Health Crisis in New Memoir

Actor Joe Manganiello has released excerpts from his upcoming memoir, 'Bloodlines,' alleging that his ex-wife, Sofía Vergara, mocked him during a severe, seven-year autoimmune illness that nearly killed him. Manganiello claims Vergara ridicged him for adopting a dog and refused to embrace him while he was sick. He disputes her previous public claims that their divorce resulted from disagreements over having children, stating instead that his health issues forced him to abandon the idea of parenthood. The actor, now symptom-free, credits a shaman and surgery for his recovery and is considering children with his fiancée, Caitlin O’Connor.

via Page Six|

#autoimmune-disease #bloodlines-memoir #celebrity-divorce

biopharmaceuticals7 days ago

Novartis Secures Chinese mRNA Therapy in $7.8B Deal Amid Pipeline Pressures

Novartis has agreed to pay up to $7.8 billion for exclusive worldwide rights to ABO2203, an early-stage mRNA-based T-cell engager developed by Chinese biotech Abogen Biosciences. The agreement includes a $575 million upfront payment and up to $7.2 billion in milestone payments. The therapy targets autoimmune diseases by depleting B cells using an in vivo approach that avoids traditional manufacturing complexities. This deal follows recent setbacks in Novartis’s own CAR-T programs and reflects a broader trend of Western pharmaceutical companies partnering with Chinese developers to secure future pipeline growth.

via Endpoints News|

#abogen-biosciences #autoimmune-disease #biopharmaceuticals

biotechnology7 days ago

Novartis Acquires Chinese Autoimmune Therapy for $7.8B Amid Patent Cliff Pressures

Novartis has agreed to pay up to $7.8 billion for Abogen Biosciences' mRNA-based T-cell engager, ABO2203, targeting autoimmune diseases. The deal includes a $575 million upfront payment and grants Novartis global rights to the asset plus an option to license other RNA-platform assets. This move follows recent setbacks in Novartis's CAR-T programs and reflects a broader trend of Western pharma companies partnering with Chinese biotechs to secure future pipeline growth.

via Fierce Biotech|

#abogen-biosciences #autoimmune-disease #biotechnology

biotech11 days ago•0 min saved

Adicet Bio Reports Lupus Remissions in CAR-T Trial, Avoiding Safety Issues Seen in Rivals

Adicet Bio reported that its off-the-shelf CAR-T therapy, prula-cel, induced remission in over half of lupus patients in a Phase 1 trial. The treatment showed a favorable safety profile with no severe inflammatory events, distinguishing it from rival autologous therapies that recently faced trial pauses due to fatalities.

via Fierce Biotech|

#adicet-bio #autoimmune-disease #biotech

biotech14 days ago•3 min saved

Kyverna reports durable, safe CAR-T results as rivals face safety pauses

Kyverna Therapeutics released one-year data for its CD19 CAR-T therapy, miv-cel, showing sustained efficacy and no severe safety events in stiff person syndrome and myasthenia gravis. The results contrast with recent safety pauses at Novartis and Bristol Myers Squibb, supporting Kyverna's FDA submission for a potential first-in-class autoimmune treatment.

via Fierce Biotech|

#autoimmune-disease #biotech #car-t-therapy

healthcare1 month ago•2 min saved

Teva's IL-15 antibody shows phase 2a promise in celiac disease

Teva's anti-IL-15 antibody TEV '408 beat placebo in a phase 2a celiac trial, reducing gluten-induced intestinal damage in 50 adults with no safety signals, paving the way for phase 3 pending further analysis; the program also spans vitiligo, with broader IL-15–axis potential in autoimmune diseases.

via Fierce Biotech|

#autoimmune-disease #celiac-disease #healthcare

pharma1 month ago•25 min saved

Safety signals pause autoimmune CAR-T trials at Novartis and BMS

Novartis and Bristol Myers Squibb have paused several autoimmune CAR-T trials after inflammatory safety events were seen, including IEC-HS cases in rap-cel studies across lupus, myasthenia gravis, and multiple sclerosis, and transient inflammatory events in zola-cel programs. Both companies say the pauses are precautionary while safety data are reviewed with regulators, with cancer trials continuing. A faster production approach for CAR-Ts may influence toxicity, but the companies emphasize ongoing monitoring and a potential quick resume once reviews are complete.

via BioPharma Dive|

#autoimmune-disease #car-t #pharma

science1 month ago•6 min saved

Arthritis drug sparks notable hair regrowth in alopecia trials

An oral arthritis medication called upadacitinib demonstrated substantial hair regrowth in two international trials for severe alopecia areata, with about half of participants achieving at least 80% scalp coverage after 24 weeks; some reached complete restoration. While promising, results vary by patient and longer-term effects and safety still need assessment.

via Interesting Engineering|

#alopecia-areata #arthritis-drug #autoimmune-disease

$CD19 CAR T therapy yields B cell depletion and clinical improvement in refractory seropositive RA (phase 1)$

medicine1 month ago•33 min saved

CD19 CAR T therapy yields B cell depletion and clinical improvement in refractory seropositive RA (phase 1)

In a nonrandomized phase 1 COMPARE trial, six adults with treatment-refractory seropositive RA received a single infusion of autologous CD19 CAR T cells (mivocabtagene autoleucel) after lymphodepletion. Safety was acceptable: cytokine release syndrome was limited to grade 1–2 in all patients, with no ICANS and only one dose-limiting transaminase elevation that resolved. CD19+ B cell depletion occurred systemically, accompanied by seroconversion or reduction of autoantibodies (ACPAs and RF IgM) in most participants. Clinically, disease activity improved in all patients (median 34% DAS28-CRP reduction; remission and ACR70 responses observed in several participants). These early results support further phase 2 evaluation of CD19 CAR T cells for refractory RA.

via Nature|

#autoimmune-disease #b-cell-depletion #cd19-car-t

science1 month ago•0 min saved

Third Death Reported in China's Opaque CAR-T Trials

A patient with an autoimmune disease died after receiving an experimental CAR-T gene therapy from a Chinese biotech startup, the third fatality in China’s controversial and opaque trials, according to Endpoints News.

via Endpoints News|

#autoimmune-disease #car-t-therapy #china-biotech

business1 month ago•4 min saved

Hashimoto’s, Pregnancy, and a Pivot: Building Perelel to Support Women’s Health

An as-told-to piece about Perelel cofounder Alex Taylor: after rapid leadership roles in publishing, mounting stress coincided with Hashimoto’s disease and pregnancy, prompting her to quit, shift to a new role at Free People Movement, and eventually cofound Perelel—bootstrapped through COVID to deliver pregnancy-focused supplements and later expand to perimenopause and IVF support. She now balances motherhood and leadership with routines like daily meditation, early bedtimes, reading fiction, and strict phone discipline to reduce stress.

via Business Insider|

#autoimmune-disease #business #entrepreneurship

health2 months ago•8 min saved

Dormant viruses reawaken in severe COVID, fueling long COVID and autoimmune risks

Nature study of 1,154 hospitalized COVID-19 patients shows severe illness can reactivate dormant viruses (11 viruses detected within 40 days), notably Anelloviridae linked to long COVID, while EBV and CMV reactivation in nasal/blood samples correlate with higher mortality and complications; findings suggest viral reactivation monitoring could help prognosticate and treat acute and long COVID, though causality isn’t proven and more research is planned.

via CIDRAP|

#anelloviridae #autoimmune-disease #covid-19

life-sciences2 months ago•10 min saved

Lung-resident immune cells link genetics to autoimmune risk

Researchers analyzed over 1.1 million tissue-resident lung immune cells from 128 donors using single-cell RNA-seq, revealing that genetic risk factors shape lung immune cell function and can drive autoimmune and inflammatory disease; thousands of risk-associated genes are active in tissue cells but not in blood, and about 1,700 genes show sex-specific expression, suggesting sex-based factors in disease susceptibility.

via News-Medical|

#autoimmune-disease #genetic-risk-factors #life-sciences

world3 months ago•23 min saved

12-year-old UK girl undergoes six rounds of chemotherapy after misdiagnosis

A 12-year-old girl in Plymouth, England, endured six rounds of chemotherapy after doctors misdiagnosed her with Juvenile Dermatomyositis; the treatments were deemed unnecessary when a genetic test at Great Ormond Street Hospital showed she actually has Emory-Dreifuss muscular dystrophy (EDMD), a rare non-cancer condition. The correct diagnosis followed negative JDM tests, and her mother says financial pressures and test choices contributed to the error. The family has spent years in and out of hospital, with limited holidays or accessible housing, and EDMD currently has no cure.

via New York Post|

#autoimmune-disease #england #medical-mishaps